The FDA record identifies Restor3D as the applicant for K243643, a Traditional 510(k) with a Substantially Equivalent decision dated May 19, 2025, received November 26, 2024, and reviewed by the Orthopedic advisory committee under product code PHX. The clearance letter names the trade/device as the restor3d Reverse Total Shoulder Arthroplasty System, classified under 21 CFR 888.3660 as a shoulder joint metal/polymer semi-constrained cemented prosthesis, Class II, with product codes PHX and KWS. The filing address on the correspondence is 4001 NC-54 Hwy Suite 2160, Durham, North Carolina, and the letter is addressed to Brianna Prindle as Director of Regulatory Affairs. That correspondence address is a filing detail, not a verified headquarters. [1][2]

Documented shoulder device and its stated design intent

Restor3D's own instructions for use describe the restor3d reverse Total Shoulder Arthroplasty (rTSA) System as a reverse total shoulder prosthesis designed for patients with glenoid and/or humeral bone defect and a deficient rotator cuff, with the reverse design inverting the articulating surfaces. The same document carries a 2025 copyright notice and a document control line reading LBL-50057 Rev 02 05-2026, and lists restor3d, Inc. of Durham, NC as manufacturer with a customer service phone number and email. An earlier revision of the same instructions, LBL-50057 Rev 01 07-2025, carries the same device description language. [4][5]

A later instructions-for-use revision, LBL-50057 Rev 04 09-2026, is titled Veritas Shoulder System and states that the system consists of reverse total shoulder and hemiarthroplasty prostheses, with the reverse prosthesis described for the same bone-defect and rotator-cuff-deficiency population and the same inverted articulating surfaces. That revision also states the Veritas System has not been evaluated for safety in the MR environment, and notes that surgeons may obtain training from a qualified instructor prior to implantation, with contact routed through restor3d Customer Service. [9]

The 2025 clearance and its stated basis

K243643 was cleared as substantially equivalent on May 19, 2025, with a Traditional clearance type, no third-party review, and a summary statement indicated in the FDA record. The record lists the device name as the restor3d Reverse Total Shoulder Arthroplasty System and the applicant as Restor3D. [1]

The clearance letter states that the restor3d Reverse Total Shoulder Arthroplasty System uses similar materials and manufacturing processes as the reference device, the Kinos Axiom Total Ankle System (K240591). That comparison is the agency correspondence's characterization of materials and processes; it is not a statement of clinical performance. [2]

Recall records naming Veritas shoulder products

FDA recall database pages list a Class 2 Device Recall titled Veritas Reverse Total Shoulder Replacement and a separate Class 2 Device Recall titled Veritas Standard Reverse Total Shoulder. These entries establish that recall records exist under those product titles; the supplied pages do not provide the recalling firm, lot numbers, root cause, or the number of affected units, so those details remain unknown here. [6][7][8]

What the supplied filings do and do not establish

The supplied collection contains one linked 510(k) record, K243643, with a single Substantially Equivalent decision; that count is an as-of snapshot of the supplied filings and does not represent total company sales, total portfolio, or safety performance. No premarket approval, De Novo, or other pathway record appears in the public information, and no parent company, brand ownership, or commercial availability claim is verified by these sources. [1][8]